Register for free to listen to this article
Listen with Speechify
0:00
1:00
PARIS—Sanofi announced in late April that it has enteredinto a collaboration with the Michael J. Fox Foundation (MJFF) to conduct aclinical trial to assess the safety and tolerability of AVE 8112, a Sanofiphosphodiesterase type 4 (PDE4) inhibitor, in patients with Parkinson'sdisease.
 
 
"We hope to continue to develop relationships with privatefoundations like the Michael J. Fox Foundation to pool our resources andmaximize the potential of our drug portfolio to address unmet medical needs,"said Dr. Elias Zerhouni, president of global R&D at Sanofi, in a pressrelease announcing the collaboration.
 
 
Under the terms of the collaboration, MJFF will sponsor aPhase Ib clinical trial to assess the safety and tolerability of AVE8112 inpatients with Parkinson's disease. All data and results generated by theclinical trial will be owned by MJFF and shared with Sanofi. Further developmentplans will be based upon the results of the study. The clinical trial will beconducted at sites in the United States in Baltimore, Md., and Los Angeles.Patient enrollment in the study is expected to begin later this year.
 
 
According to Sanofi, AVE8112 has shown promisingprocognitive activity in preclinical models that could be of interest to theunder-addressed cognitive aspects of Parkinson's disease.
 
 
This "area of unmet need where a new treatment could make atangible difference in patients' lives," said Dr. Todd Sherer, CEO of MJFF, ina statement.
 
 
"Groundbreaking collaborations with like-minded partnerssuch as Sanofi are a hallmark of the Fox Foundation's approach and help usspeed scientific advances with potential to improve the treatment ofParkinson's for patients today and in the future," he added.
  


Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue